Jejunal Lymphoma – Comprehensive Medical Guide

Overview

Jejunal lymphoma is a type of non‑Hodgkin lymphoma (NHL) that originates in the lymphoid tissue of the jejunum, the middle portion of the small intestine. It is a rare gastrointestinal (GI) malignancy, accounting for roughly 1–2 % of all NHL cases and 0.2–0.5 % of all gastrointestinal cancers.^{[1] Mayo Clinic} Lymphoma cells grow in the wall of the jejunum, potentially infiltrating surrounding tissue and causing obstruction, bleeding, or perforation.

Who is affected? The disease can occur at any age but shows a bimodal distribution:

• Children and adolescents: Often associated with immunodeficiency syndromes (e.g., congenital immune defects, HIV) and certain viral infections such as Epstein‑Barr virus (EBV).
• Adults (median age 55‑65 years): More frequently linked to chronic inflammatory conditions (e.g., celiac disease) and lifestyle‑related risk factors.

Men are slightly more likely to develop jejunal lymphoma than women (ratio ≈ 1.3:1).^{[2] WHO Classification of Tumours}

Symptoms

Because the jejunum is a deep abdominal structure, early disease may be silent. When symptoms arise, they tend to be vague and may mimic other GI disorders.

Common symptoms

• Abdominal pain or cramping – often intermittent, may worsen after meals.
• Unexplained weight loss – loss of appetite plus increased metabolic demand.
• Night sweats – drenching sweats unrelated to exercise or temperature.
• Fatigue – from anemia, cytokine release, or malnutrition.
• Persistent diarrhea or constipation – altered bowel habits from partial obstruction.
• Occult or overt gastrointestinal bleeding – melena, hematochezia, or iron‑deficiency anemia.

Less common but important signs

• Abdominal distension or a palpable mass.
• Feeling of early satiety (full quickly after eating).
• Fever of unknown origin.
• Peripheral neuropathy (rare, associated with certain NHL subtypes).

Symptoms often develop slowly over weeks to months, which can delay diagnosis.

Causes and Risk Factors

Jejunal lymphoma arises from malignant transformation of B‑ or T‑lymphocytes within the intestinal mucosa-associated lymphoid tissue (MALT). The exact cause is multifactorial.

Primary causes

• Chronic inflammation of the small intestine – conditions such as celiac disease create a milieu of immune activation that can lead to MALT lymphoma.^{[3] Cleveland Clinic}
• Viral infections – Epstein‑Barr virus (EBV) and human immunodeficiency virus (HIV) increase lymphoma risk.
• Immunosuppression – organ‑transplant recipients on calcineurin inhibitors, patients on long‑term steroids, or those with primary immunodeficiency.
• Genetic predisposition – inherited DNA repair defects (e.g., ATM, DNA‑PKcs) raise susceptibility.

Risk factors

• Age > 50 years (for adult‑type peripheral B‑cell lymphomas).
• Male sex (slightly higher incidence).
• History of celiac disease or other autoimmune enteropathies.
• Long‑standing inflammatory bowel disease (IBD), though more common in colon‑linked lymphomas.
• Exposure to certain chemicals (pesticides, herbicides) – data limited but suggested in occupational studies.
• Family history of lymphoma or other hematologic malignancies.

Diagnosis

Diagnosing jejunal lymphoma requires a combination of clinical suspicion, imaging, endoscopic evaluation, and tissue pathology.

Initial work‑up

• Complete blood count (CBC) and metabolic panel – assesses anemia, electrolytes, liver/kidney function.
• Serologic tests – HIV, EBV PCR, and celiac serology (tTG‑IgA) when indicated.

Imaging studies

• CT scan of the abdomen and pelvis – detects wall thickening, masses, lymphadenopathy, and possible perforation.
• Magnetic resonance enterography (MRE) – provides high‑resolution images of the small bowel without radiation.
• Positron emission tomography (PET‑CT) – evaluates metabolic activity, stages disease (Ann‑Arbor staging), and monitors treatment response.

Endoscopic & tissue sampling

• Capsule endoscopy – visualizes the entire small intestine; useful when conventional endoscopy is negative.
• Double‑balloon enteroscopy (DBE) – allows direct visualization and biopsy of jejunal lesions.
• Radiologic‑guided core needle biopsy – percutaneous biopsy of a mass identified on CT/MRI.

Pathology

Biopsy specimens undergo:

• Histologic classification (e.g., diffuse large B‑cell lymphoma, mantle‑cell lymphoma, enteropathy‑associated T‑cell lymphoma).
• Immunophenotyping (CD20, CD3, Ki‑67, etc.) to determine cell origin.
• Genetic studies (FISH, PCR) for translocations (e.g., t(11;14) in mantle‑cell lymphoma).

Staging

The standard Ann‑Arbor system (Stages I–IV) is used, supplemented with the Lugano classification for GI lymphomas, which incorporates depth of wall invasion and extra‑intestinal spread.

Treatment Options

Treatment is individualized based on lymphoma subtype, stage, patient fitness, and presence of complications.

1. Chemotherapy

• CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) – backbone for most B‑cell lymphomas.^{[4] NIH}
• R‑CHOP – adds rituximab (anti‑CD20 monoclonal antibody) for CD20‑positive tumors, improving overall survival by 10–15 %.
• For aggressive T‑cell lymphomas, regimens such as ICE (ifosfamide, carboplatin, etoposide) may be used.

2. Targeted therapy

• Rituximab – standard for CD20‑positive B‑cell disease.
• Brentuximab vedotin – for CD30‑positive anaplastic large‑cell lymphoma.
• Lenalidomide or ibrutinib – investigational in relapsed/refractory cases.

3. Radiation therapy

Low‑dose involved‑field radiation (24–30 Gy) may be added after chemotherapy for localized disease (Stage I–II) or for palliation of painful masses.

4. Surgery

• Primarily for complications: bowel obstruction, perforation, or uncontrolled bleeding.
• In selected early‑stage, localized tumors, surgical resection followed by adjuvant chemotherapy can achieve cure rates > 70 %.

5. Stem cell transplantation

High‑dose chemotherapy followed by autologous stem‑cell rescue is considered for relapsed or refractory disease, especially in younger patients.

6. Supportive & lifestyle measures

• Nutrition: high‑protein, low‑fiber diet during active treatment to minimize bowel irritation.
• Growth factor support (e.g., filgrastim) to reduce chemotherapy‑induced neutropenia.
• Vaccinations (influenza, pneumococcal) before immunosuppressive therapy.
• Psychosocial counseling – coping with a cancer diagnosis.

Living with Jejunal Lymphoma

Long‑term management extends beyond finishing chemotherapy.

Follow‑up care

• Clinic visits every 3–4 months for the first two years, then every 6 months up to five years.
• Physical exam, CBC, LDH, and PET‑CT or CT at intervals to detect recurrence.

Nutrition and digestion

• Work with a registered dietitian to ensure adequate caloric intake; consider oral nutrition supplements if weight loss persists.
• Small, frequent meals may reduce cramping and improve absorption.
• Monitor for lactose intolerance or malabsorption, common after jejunal involvement.

Managing side effects

• Peripheral neuropathy – dose‑adjust chemotherapy, use gabapentin or duloxetine.
• Fatigue – balance activity with rest; gentle aerobic exercise when tolerated.
• Infection risk – practice hand hygiene, avoid crowds during neutropenic periods, and keep a list of emergency antibiotics.

Emotional well‑being

• Join support groups (e.g., Lymphoma Research Foundation).
• Consider counseling or cognitive‑behavioral therapy for anxiety or depression.

Prevention

Because many risk factors are non‑modifiable, prevention focuses on reducing modifiable contributors and early detection.

• Manage celiac disease aggressively – strict gluten‑free diet lowers the incidence of enteropathy‑associated T‑cell lymphoma (EATL).^{[5] CDC}
• Avoid prolonged immunosuppression when possible; discuss dose‑reduction strategies with your physician.
• Vaccinate against EBV (experimental) and hepatitis B, which can indirectly lower lymphoma risk.
• Healthy lifestyle – balanced diet rich in fruits/vegetables, regular exercise, and avoidance of tobacco/alcohol decrease overall cancer risk.
• Regular medical surveillance for individuals with known high‑risk conditions (e.g., refractory celiac disease, HIV).

Complications

If left untreated or inadequately treated, jejunal lymphoma can lead to serious complications:

• Intestinal obstruction – severe abdominal pain, vomiting, inability to pass gas or stool.
• Perforation – sudden severe pain, peritonitis, fever; requires emergency surgery.
• Massive gastrointestinal bleeding – melena or hematochezia leading to anemia or hypovolemic shock.
• Malabsorption – chronic nutrient deficiencies (iron, B12, fat‑soluble vitamins).
• Secondary infections – due to chemotherapy‑induced immunosuppression.
• Transformation to high‑grade lymphoma – especially in indolent MALT forms.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe abdominal pain that does not improve with rest.
• Vomiting that is greenish, contains blood, or is persistent.
• Bright red blood per rectum or black, tarry stools (melena).
• Fever > 38.5 °C (101.3 °F) with chills, especially if you have a low white‑blood‑cell count.
• Rapid heart rate, dizziness, or fainting – signs of shock.
• Swelling of the abdomen or inability to pass gas or stool for > 24 hours.

References

1. Mayo Clinic. “Small intestine lymphoma.” Accessed May 2026. https://www.mayoclinic.org/diseases‑conditions/small‑intestine‑lymphoma
2. World Health Organization. “Classification of Tumours of Haematopoietic and Lymphoid Tissues,” 5th edition, 2022.
3. Cleveland Clinic. “Celiac disease and lymphoma risk.” 2023. https://my.clevelandclinic.org/health/diseases/16647-celiac-disease
4. National Cancer Institute. “Non‑Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version.” Updated 2024.
5. Centers for Disease Control and Prevention. “Celiac Disease.” 2023. https://www.cdc.gov/celiac/